Robert H Diamond
Overview
Explore the profile of Robert H Diamond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
2302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montgomery M, van Santen M, Biemond B, Diamond R, Pals S
Gastroenterol Hepatol (N Y)
. 2016 Apr;
11(3):160-3.
PMID: 27099586
Hepatosplenic T-cell lymphoma (HSTCL) is a rare malignancy of unknown incidence that has been associated with immune-mediated disease. This study explored the incidence and patient characteristics of HSTCL in a...
2.
Cornillie F, Hanauer S, Diamond R, Wang J, Tang K, Xu Z, et al.
Gut
. 2014 Jan;
63(11):1721-7.
PMID: 24474383
Background: Serum infliximab trough levels correlate with efficacy; dose escalation is often beneficial in patients with Crohn's disease who stop responding to infliximab treatment. Objective: To carry out a post...
3.
Lichtenstein G, Feagan B, Cohen R, Salzberg B, Diamond R, Langholff W, et al.
Am J Gastroenterol
. 2014 Jan;
109(2):212-23.
PMID: 24394749
Objectives: We assessed potential associations between malignancy and antitumor necrosis factor therapy in patients with Crohn's disease (CD), as this relationship is currently poorly defined. Methods: Utilizing data from the...
4.
Ferrante M, Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, et al.
Gastroenterology
. 2013 Aug;
145(5):978-986.e5.
PMID: 23954314
Background & Aims: Mucosal healing might alter midterm and long-term outcomes of patients with Crohn's disease (CD) and has become an important end point in clinical trials. However, the minimal...
5.
Lichtenstein G, Feagan B, Cohen R, Salzberg B, Diamond R, Price S, et al.
Am J Gastroenterol
. 2012 Aug;
107(9):1409-22.
PMID: 22890223
Objectives: The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD). Methods: We prospectively evaluated CD patients enrolled in the...
6.
Lichtenstein G, Rutgeerts P, Sandborn W, Sands B, Diamond R, Blank M, et al.
Am J Gastroenterol
. 2012 May;
107(7):1051-63.
PMID: 22613901
Objectives: The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and ulcerative colitis (UC) clinical trials. Methods: To...
7.
Keshavarzian A, Mayer L, Salzberg B, Garone M, Finkelstein W, Cappa J, et al.
Gastroenterol Hepatol (N Y)
. 2011 Oct;
3(5):381-90.
PMID: 21960854
Background: Infusion reactions have been associated with infliximab therapy, but no study has assessed how physicians treat and manage this common adverse event. Goals: To determine how gastroenterologists manage infusion...
8.
Esser D, Cornillie F, Diamond R, Spiegel R
J Crohns Colitis
. 2011 Apr;
5(2):165-6.
PMID: 21453888
No abstract available.
9.
Kotlyar D, Blonski W, Diamond R, Wasik M, Lichtenstein G
Am J Gastroenterol
. 2010 Oct;
105(10):2299-301.
PMID: 20927075
No abstract available.
10.
Kotlyar D, Osterman M, Diamond R, Porter D, Blonski W, Wasik M, et al.
Clin Gastroenterol Hepatol
. 2010 Oct;
9(1):36-41.e1.
PMID: 20888436
Background & Aims: Hepatosplenic T-cell lymphoma (HSTCL) is a rare and usually fatal lymphoma that primarily affects men younger than 35 years old. Treatment of patients with inflammatory bowel disease...